806 related articles for article (PubMed ID: 27862107)
1. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
Mao EJ; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 Jan; 45(1):3-13. PubMed ID: 27862107
[TBL] [Abstract][Full Text] [Related]
2. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
[TBL] [Abstract][Full Text] [Related]
4. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis.
Khan KJ; Dubinsky MC; Ford AC; Ullman TA; Talley NJ; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):630-42. PubMed ID: 21407186
[TBL] [Abstract][Full Text] [Related]
7. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis.
Shah ED; Farida JP; Siegel CA; Chong K; Melmed GY
Inflamm Bowel Dis; 2017 Apr; 23(4):570-577. PubMed ID: 28230558
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
[TBL] [Abstract][Full Text] [Related]
9. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases.
Han M; Jung YS; Cheon JH; Park S
J Gastroenterol Hepatol; 2019 Jul; 34(7):1166-1174. PubMed ID: 30672608
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis comparing the efficacy and adverse events of biologics and thiopurines for Crohn's Disease after surgery for ulcerative colitis.
Yadav A; Kurada S; Foromera J; Falchuk KR; Feuerstein JD
Dig Liver Dis; 2018 Oct; 50(10):1004-1011. PubMed ID: 29903546
[TBL] [Abstract][Full Text] [Related]
11. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
[TBL] [Abstract][Full Text] [Related]
12. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
Renna S; Cottone M; Orlando A
World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
[TBL] [Abstract][Full Text] [Related]
13. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
14. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
[No Abstract] [Full Text] [Related]
16. How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort.
Ott C; Takses A; Obermeier F; Schnoy E; Salzberger B; Müller M
Int J Colorectal Dis; 2014 Nov; 29(11):1329-38. PubMed ID: 25179426
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis.
Gupta V; Rodrigues R; Nguyen D; Sauk J; Khalili H; Yajnik V; Ananthakrishnan AN
Aliment Pharmacol Ther; 2016 Jan; 43(1):52-60. PubMed ID: 26541937
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
Williams CJ; Peyrin-Biroulet L; Ford AC
Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171
[TBL] [Abstract][Full Text] [Related]
19. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
[TBL] [Abstract][Full Text] [Related]
20. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
